NCT00638378View on ClinicalTrials.gov

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Prostate Cancer
Interventions
DRUG

Ruxolitinib

Ruxolitinib 25 mg tablets taken with water twice a day.

Trial Locations (15)

59405

Great Falls

Unknown

Highland

Montebello

Mountain View

Galesburg

Overland Park

Wichita

Grand Rapids

Jefferson City

Cherry Hill

Staten Island

Bismarck

Bethlehem

Sumter

Lacey

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT00638378 - Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter